The purpose of the currents study was to enhance bioavailability of rivaroxaban (RXB) and
reduce the food effect. RXB loaded PLGA nanoparticles (RXB-PLGA-NPs) were prepared by …

Rivaroxaban (RVX), an oral direct factor Xa inhibitor, is being explored as an alternative to
traditional anticoagulans. However, RVX still faces pharmacokinetic limitations and adverse …

Rivaroxaban (RXB), an oral direct factor Xa inhibitor, presents innovative therapeutic profile.
However, RXB has shown adverse effects, mainly due to pharmacokinetic limitations …

This study aims to improve the RXB bioavailability using hybrid nanoparticles. A modified
melt dispersion technique created different formulas with varying GMO-SAIB: RXB and GMO …

Rivaroxaban (RXN) finds use in the management of pulmonary embolism and deep vein
thrombosis. Its poor solubility (5–7 µg/mL) and P-gp-mediated efflux from intestinal lining …

Objectives Rivaroxaban (RXB), a novel Xa inhibitor having groundbreaking therapeutic
potential. However, this drug is associated with few limitations, including its …

Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor
Xa, given as monotherapy in the treatment of venous thromboembolism (VTE). It has been …

This study aimed to investigate the use of Sucrose acetate isobutyrate (SAIB) and Glyceryl
monooleate (GMO) as co-formers for creating Cubosomes and SAIB-based nanodispersions …

The objective of the present study was to evaluate the potential of solid dispersion adsorbate
(SDA) to improve the solubility and bioavailability of rivaroxaban (RXN). SDA of RXN was …

Rivaroxaban (RXB) is a direct factor Xa inhibitor used for the treatment of deep vein
thrombosis (DVT, a blood clot in the leg) and pulmonary embolism (PE, a blood clot in the …